A Study to Evaluate Safety and Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot Ulcer

NCT ID: NCT04277598

Last Updated: 2024-01-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 159 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-09
• Study Completion Date: 2023-12-06

Brief Summary

The MARSYAS II study which will be conducted in patients with diabetic foot ulcer (DFU) consists of a Lead-In Phase for safety assessment of multiple doses of the biologic investigational medicinal product (IMP) APO-2 and of a Main Phase (Phase II Study) to assess the efficacy and safety of the IMP. The phase II study will be a randomized study at multiple clinical centers and it will be double-blind meaning that neither the investigator nor the treated patient know if the IMP or a placebo is applied; the study will investigate the safety and clinical efficacy of multiple dose administrations at three dose levels of APO-2 (low dose, medium dose or high dose) compared with placebo.

Detailed Description

APOSEC is a secretome released by cultured, stressed peripheral blood mononuclear cells (PBMC) in medium. Content analysis revealed that APOSEC harbors a myriad of proteins, exosomes, lipids, phospholipids, cholesterols as well as antimicrobial peptides. It was shown that the topical application of APOSEC mixed with a hydrogel, called APO-2, promotes/enhances wound healing.

The MARSYAS II main study will be a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-ranging phase II study to investigate the safety and clinical efficacy of multiple dose administrations at three dose levels of APO-2 compared with placebo in patients with diabetic foot ulcer (DFU).

The main study will be preceded by a safety lead-in period evaluating multiple dose safety (25 U/ml APO-2) in patients with DFU in a cohort of 12 patients randomized at a ratio of 3:1 between APO-2 and placebo at 2 to 4 study sites. The minimum duration of an individual patient in the safety lead-in period is 93 days (including screening), with a maximum of approximately 117 days.

In the main study 120 eligible patients will be randomized at a ratio of 1:1:1:1 between APO-2 (three doses) and placebo. Patients will be stratified by wound size (at least 20% of patients will need to have wound size > 4 square cm), and randomly assigned to 1 of 4 treatment groups (low dose [12.5 U/ml], medium dose [25 U/ml], high dose [50 U/ml] or placebo). After randomization, patients will receive IMP three times per week during the 4-week active treatment period. 0.5 ml IMP will be applied per square cm wound surface area for each dose group.

Conditions

Diabetic Foot Ulcer (DFU)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Lead In Phase: APO-2: 25U/ml

Topical administration of APO-2, 25 U/ml; Approximalety 0.5 ml per square cm wound;

Group Type: EXPERIMENTAL

APO-2

Intervention Type: BIOLOGICAL

APO-2: dose adjusted gel for topical administration.

Lead In Phase: Placebo

Topical administration of placebo; Approximalety 0.5 ml per square cm wound;

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo gel for topical administration.

Main Phase: APO-2: 12.5 U/ml

Topical administration of APO-2, 12.5 U/ml; Approximalety 0.5 ml per square cm wound;

Group Type: EXPERIMENTAL

APO-2

Intervention Type: BIOLOGICAL

APO-2: dose adjusted gel for topical administration.

Main Phase: APO-2: 25 U/ml

Topical administration of APO-2, 25 U/ml; Approximalety 0.5 ml per square cm wound;

Group Type: EXPERIMENTAL

APO-2

Intervention Type: BIOLOGICAL

APO-2: dose adjusted gel for topical administration.

Main Phase: APO-2: 50 U/ml

Topical administration of APO-2, 50 U/ml; Approximalety 0.5 ml per square cm wound;

Group Type: EXPERIMENTAL

APO-2

Intervention Type: BIOLOGICAL

APO-2: dose adjusted gel for topical administration.

Main Phase: Placebo

Topical administration of placebo; Approximalety 0.5 ml per square cm wound;

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo gel for topical administration.

Interventions

APO-2

APO-2: dose adjusted gel for topical administration.

Intervention Type: BIOLOGICAL

Placebo

Placebo gel for topical administration.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Patient is between 18 and 80 years of age

2. Patients with Type I or Type II diabetes with a glycosylated hemoglobin (HbA1c) of ≤ 12 %, obtained at enrollment or within 30 days prior to study enrollment

3. Patients who have a wound defined as diabetic foot ulcer present for ≥ 4 weeks

4. Foot ulcer Wagner grade I - II or ARMSTRONG grade I-A (superficial, non-infected, non-ischemic wound not involving tendon, capsules, or bone) or II-A (non-infected, non-ischemic wound penetrating to tendon or capsule but not to the bone or joint)

5. Estimated foot ulcer surface area between ≥ 0.8 cm2 and ≤ 8 cm2 as measured at day of randomization assessed using the eKare imaging and measurement device

7. Wound area has not changed by more than 30 % between screening visit and randomization visit (at least 14 days)

8. Adequate arterial blood perfusion measured on the leg with treated wound (ABI [ankle brachial index] ≥0.5 [the lowest ABI measured value will be used as reference], or toe pressure > 40 mmHg, or tcPO2 > 40 mmHg) within the past 6 months including patients with mild to moderate peripheral arterial disease (Fontaine Stage I and II)

9. Patient must adhere to off-loading of the ulcer area (in mobile patients adherence to off-loading footwear during the study is mandatory)

10. Patient is able to give written informed consent prior to study start and to comply with the study requirements

11. Women of childbearing potential agree using adequate birth control methods during the study

Exclusion Criteria

1. History of anaphylaxis, known hypersensitivity to sodium alginate, propylene glycol, methylene-blue or chicken-egg

2. Target ulcer is over a deformity (such as Charcot deformity) that interferes with off-loading based on investigator's opinion

3. Index wound duration of > 3 years without intermittent healing

4. Clinical evidence of ulcer bed infection or patients requiring intravenous (IV) antibiotics to treat the index wound infection at time of randomization

5. Current evidence of osteomyelitis, cellulitis, or other evidence of infection including pus drainage from the wound site, or documented history of osteomyelitis at the target wound location during the 8 weeks preceding the screening visit

6. Major uncontrolled medical disorder(s) such as severe uncontrolled leg edema, concurrent medication, or other issue that renders the patient unsuitable for participation in the study, including but not limited to: comorbid condition with an estimated life expectancy of ≤ 12 months, hemoglobin A1c (Hba1c) > 12 % at screening, patients on dialysis, patients with severe pulmonary (requiring home oxygen, uncontrolled COPD Gold III/ IV) or cardiovascular conditions (heart failure NYHA IV, uncontrolled hypertension systolic BP by repeated measurement > 180 mmHg)

7. Raynaud disease or any other severe peripheral microvascular disease, current diagnosis of vasculitis

7a. Patients with PAD who

• have not been assessed by vascular imaging as per standard of care or
• have acute peripheral artery occlusion of the index extremity or
• have PAD Fontaine Stage III and IV or
• have PAD with planned revascularization during the upcoming 6 months or
• had Angioplasty for re-perfusion in the lower extremity with target ulcer during 3 months preceding the screening visit

8. Dermatologic comorbid disease (e.g. pyoderma gangrenosum, vasculopathy or vasculitic ulcers), history of Systemic Lupus Erythematosus with elevated anti-DNA antibody titers, Buerger's disease (thromboangiitis obliterans)

9. Patient currently treated for an active malignant disease or prior diagnosis of an active malignant disease who is disease free for less than 1 year. Treatment with anticancer therapy (chemotherapy, immunotherapy, radiotherapy, targeted therapy or gene therapy) within 3 months before the first administration of investigational product or at any time during the study.

10. Patient with history of malignancy within the wound; history of radiation therapy to the wound region

11. Patients who have undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days or during the study

12. Patients who received oral or parenteral corticosteroids, immunosuppressants, or cytotoxic agents within 30 days preceding the first study drug administration, or plan to use these medications during the study period

13. Patients who are pregnant or breastfeeding

14. Mental condition rendering the patient (or the patient's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study

15. Patients who are incarcerated, including prisoners or patients compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness

16. Therapy with another investigational agent within thirty days of screening, or during the study

17. Patients who are considered by the investigator to have a significant disease, which can impact the study; patients who are considered not suitable for the study by the investigator

18. Employee at the study site, spouse/partner or relative of any study staff (e.g. investigator, sub-investigators, or study nurse) or relationship to the sponsor

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

FGK Clinical Research GmbH

INDUSTRY

Sponsor Role: collaborator

Aposcience AG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hendrik J Ankersmit, Univ.Prof.Dr.

Role: STUDY_DIRECTOR

Aposcience AG

Locations

LKH-Universitätsklinikum Graz; Klinische Abteilung für Plastische, Ästhetische und Rekonstruktive Chirurgie

Graz, , Austria

Medizinische Universität Innsbruck; Univ.-Klinik für Gefäßchirurgie

Innsbruck, , Austria

A.ö. Krankenhaus der Elisabethinen Klagenfurt GmbH; Abteilung für Chirurgie

Klagenfurt, , Austria

Kepler Universitätsklinikum Linz; Klinik für Dermatologie und Venerologie

Linz, , Austria

Clinic Hietzing; Wiener Gesundheitsverbund

Vienna, , Austria

Klinikum Wels-Grieskirchen; Abteilung für Haut- und Geschlechtskrankheiten

Wels, , Austria

University hospital at St. Anny; Fakultní nemocnice u sv. Anny

Brno, , Czechia

University hospital Vinohrady

Prague, , Czechia

Central military hospital - Military university hospital Prague

Prague, , Czechia

Masaryk hospital in Usti nad Labem

Ústí nad Labem, , Czechia

Universitätsklinikum Essen, Klinik für Endokrinologie und Stoffwechselerkrankungen

Essen, , Germany

NZOZ "Mikomed"

Lodz, , Poland

Podos clinic

Warsaw, , Poland

Pracownia Badań Klinicznych Salus

Wroclaw, , Poland

Countries

Austria; Czechia; Germany; Poland

References

Gugerell A, Gouya-Lechner G, Hofbauer H, Laggner M, Trautinger F, Almer G, Peterbauer-Scherb A, Seibold M, Hoetzenecker W, Dreschl C, Mildner M, Ankersmit HJ. Safety and clinical efficacy of the secretome of stressed peripheral blood mononuclear cells in patients with diabetic foot ulcer-study protocol of the randomized, placebo-controlled, double-blind, multicenter, international phase II clinical trial MARSYAS II. Trials. 2021 Jan 6;22(1):10. doi: 10.1186/s13063-020-04948-1.

Reference Type: DERIVED

PMID: 33407796 (View on PubMed)

Other Identifiers

MARSYAS II

Identifier Type: -

Identifier Source: org_study_id